What Alpha-Ketoglutarate Is—and Whether It's Safe for Aging Dogs
Medically reviewed by Betsy Hershey, DVM, DACVIM (Oncology), CVA — For general education — not a substitute for veterinary care.
Alpha-ketoglutarate is a real metabolite with real mouse data behind it, but "safe and studied in dogs" are not yet the same claim.
On this page
An 11-year-old, 62-pound Labrador retriever comes in for her annual senior workup. Bloodwork is unremarkable, her joints are stiff but manageable, and her owner has a browser tab open to a supplement claiming to “reverse aging” with alpha-ketoglutarate. He wants to know, plainly, whether to add it to her bowl. That question—not the marketing copy—is the one worth answering carefully.
What alpha-ketoglutarate actually is
Alpha-ketoglutarate (AKG) is not an exotic import. It’s a metabolite your dog’s cells already make and use every day, generated in the Krebs cycle as cells convert nutrients into usable energy. It also plays a role in amino acid metabolism and collagen synthesis. That endogenous status is exactly why the safety conversation is more nuanced than “new ingredient, unknown risk”—the body isn’t meeting AKG for the first time. What’s new is the idea of supplementing it in a calcium-buffered form, at doses well above what normal metabolism produces, to see whether that shifts the trajectory of aging itself.
What the mouse data actually shows
The foundational study here comes from researchers at the Buck Institute, published in Cell Metabolism. In aged mice given calcium alpha-ketoglutarate (Ca-AKG), the treated group lived longer and, notably, spent more of that extra time in good health rather than declining—what the Cell Metabolism / PubMed: Cell Metabolism paper frames as a compression of morbidity rather than a simple lifespan bump. The proposed mechanism runs through reduced systemic inflammation, including a drop in inflammatory cytokines. That’s a genuinely interesting result. It is also a mouse result, run at a specific dose in a specific strain, and mouse metabolism is not dog metabolism laid over a different-shaped body.
I once worked through a similar gap with an owner who’d already started her 9-year-old terrier mix on a human NAD+ precursor product, reasoning that “cellular support” was cellular support regardless of species or dose. Six weeks in, nothing had visibly changed except her confidence that it was working. We backed off, checked labs, and rebuilt the plan around what was actually indicated for that dog’s joints and kidney values. The lesson wasn’t that the ingredient was dangerous—it’s that borrowing a human dose or a mouse mechanism and applying it to a dog without species-specific data is a tradeoff, not a shortcut, and it can substitute confidence for evidence.
Where the human trials stand
Human research on AKG has moved further than the canine research has. A registered trial, ClinicalTrials.gov: Does Alpha-ketoglutarate Supplementation Lower BiologicaL agE in Middle-Aged Adults? (ABLE), is a double-blind, placebo-controlled study examining whether calcium alpha-ketoglutarate reduces DNA methylation age in people, with safety monitoring built in for liver and kidney function. That’s a meaningfully different evidence tier than a mouse study—closer to what regulators and clinicians want to see—but it still isn’t a dog study, and biological-age biomarkers in people don’t automatically translate into a validated readout for canine aging.
The closest thing to a dog-specific answer
The most direct canine longevity work underway right now doesn’t actually involve AKG as an over-the-counter supplement—it involves a related compound in a conditionally regulated drug candidate. Loyal, a veterinary biotech company, is running the STAY trial, a large, blinded, placebo-controlled study enrolling roughly 1,000 to 1,300 senior dogs across dozens of practices, evaluating a drug intended to extend healthy lifespan by targeting age-related metabolic decline. It’s being developed for dogs age 10 and up weighing at least 14 pounds, administered as a prescribed daily pill rather than a shelf supplement. That distinction matters: a compound moving through veterinary drug development, with Target Animal Safety data submitted to the FDA, sits on different regulatory footing than an ingredient added to a chew because a mouse paper looked promising.
Here’s where the edge case shows up in practice. A 13-year-old, 48-pound mixed-breed dog with mild chronic kidney disease is exactly the patient where “AKG is endogenous, so it’s inherently safe” stops being a sufficient answer—amino acid and nitrogen metabolism intersect with kidney function, and a dog with reduced renal reserve is not the same physiological system as a healthy laboratory mouse. By the three-week mark on any new longevity supplement in a dog like this, I want a recheck of kidney values, not just an owner’s impression that her coat looks shinier. The mechanism that looks clean in a healthy model can behave differently once an organ system is already compromised, which is exactly why species- and case-specific data, not extrapolation, has to drive the decision.
Where that leaves an owner today
For a healthy senior dog, the biological plausibility of AKG is real: it’s an endogenous metabolite with a published mouse longevity study and human trials now underway to test the same mechanism. What doesn’t exist yet is a published, dog-specific safety or efficacy trial for AKG as a supplement at a defined canine dose. That gap is worth sitting with rather than talking around. Until it closes, I tell owners to treat AKG the way we treat most emerging longevity compounds in dogs: promising signal, not yet a settled answer, and not a substitute for the basics that already have decades of veterinary evidence behind them—appropriate joint support, weight management, and routine senior bloodwork. If your dog has kidney disease, is on other supplements, or is already showing cognitive or mobility changes, that’s a conversation for your veterinarian before it’s a purchase decision.
Other structure/function ingredients get asked about in the same senior-wellness conversation, and the evidence quality varies by ingredient. For joint-specific comparisons, see how collagen stacks up against glucosamine or how avocado-soy unsaponifiables compare to glucosamine for cartilage support. And if an owner is tempted to repurpose a human supplement cabinet for a senior dog, the same caution that applies to AKG applies to swapping human B12 for a dog-formulated chew: endogenous or naturally occurring doesn’t automatically mean interchangeable across species and doses.
So is alpha-ketoglutarate safe for aging dogs? What would it take—one well-designed canine dosing and safety study—before that question has a real answer instead of a plausible one?
Frequently asked questions
Is alpha-ketoglutarate the same thing as NAD+ or NMN?
No. AKG is a Krebs-cycle metabolite involved in energy production and amino acid metabolism, while NAD+ precursors like NMN and nicotinamide riboside work through a different pathway tied to cellular energy and repair enzymes. They're both discussed in the longevity-supplement space, but they aren't interchangeable compounds.
Has alpha-ketoglutarate been tested in dogs specifically?
Not yet in a published, dog-specific safety or efficacy trial at a defined dose. The strongest data are a mouse lifespan study and ongoing human trials; canine research on AKG as a supplement is still emerging.
Should I ask my vet before giving my senior dog an AKG supplement?
Yes, especially if your dog has kidney disease, is on other medications or supplements, or has any chronic condition. A veterinarian can weigh the plausible benefit against your dog's specific labwork and history.